The group's principal activity is to develop and commercialize therapeutic products based on drug delivery technologies. The group has several areas of focus including controlled, extended-release of injectable drugs using prolease(R) and medisorb(R) delivery systems, and the development of pharmaceutical products based on its proprietary advanced inhalation research (air) pulmonary technology. Medisorb(R) is used for encapsulating traditional small molecule pharmaceuticals in microspheres made of common medical polymers. Air (TM) technology system enables the delivery of both small molecules and macromolecules to the lungs. Cereport(R) drug delivery system increases transiently the permeability of the blood-brain barrier.
Executive Information
Name
Title
Email
Gordon Pugh
COO, Sr. VP
N/A
James Frates
Sr. VP, CFO, Treasurer
N/A
Kathryn Biberstein
Sr. VP, General Counsel, Sec., Chief Compliance Officer
N/A
Elliot Ehrich
Sr. VP - Research, Development, Chief Medical Officer
